Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
30/05/2025
Synopsys has suspended the release of its third quarter financial guidance and full year financial guidance.
Latest
2 m ago
Germany plans to impose a 10% digital tax on tech giants such as Google.
3 m ago
502025616 ( The Beijing Stock Exchange and China Securities Index Company: Regular adjustments will be made to the sample stocks and backup list of the BeiZeng 50 Index, which will officially take effect on June 16, 2025.)
3 m ago
Sentrans gathered a 73% year-on-year increase in gross profit in the first quarter of 2025. Digital LiDAR technology has been adopted by 17 vehicle models, and income from robots has doubled.
3 m ago
Chen Zhu, a researcher at CITIC Securities: There is great potential for Chinese innovative drugs to go global, and the pharmaceutical industry is expected to continue its growth momentum in the second half of the year.
3 m ago
Chen Zhu, Chief Analyst of Medical Health Industry at Citic Securities, stated that in the first half of 2025, the pharmaceutical sector showed the best market returns in the past three years. Benefiting from the improving external environment for medicine and the accelerated harvest period for domestic innovative drugs, it is expected that the performance and valuation recovery trend of the medical health industry in the second half of 2025 will be relatively certain. Many Chinese innovative drug companies have demonstrated strong potential for international expansion and are constantly increasing their asset value through licensing deals and other models to compete in the global innovative drug market.
See all latest
